SAMe
S-adenosylmethionine — sold as a supplement in the US, prescribed as a drug in Europe. One of the most underappreciated mood and joint compounds with a substantial evidence base.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any supplement.
S-adenosylmethionine (SAMe, pronounced "Sammy") is a naturally occurring compound synthesised in every cell of the body from the amino acid methionine and ATP. It serves as the primary methyl donor in over 100 enzymatic reactions — the biochemical process of transferring a methyl group (-CH₃) to other molecules, which regulates everything from neurotransmitter synthesis to DNA expression to membrane fluidity.
SAMe is not a herb or a vitamin — it's an endogenous molecule that your body makes and uses constantly. When SAMe donates a methyl group, it becomes S-adenosylhomocysteine (SAH), which is then converted to homocysteine. Homocysteine is then recycled back to methionine via the folate and B12 cycle — which is why adequate B12 and folate are essential for SAMe metabolism to work efficiently.
In the US, SAMe is sold as an over-the-counter supplement. In Germany and Italy, it has been a prescription medication since the 1970s — one of the most telling regulatory divergences in the supplement world, reflecting how seriously European clinicians take its pharmacological activity.
- Depression (mild to moderate): This is SAMe's most evidence-rich application. A 2002 AHRQ evidence review of 47 randomised trials concluded that SAMe was significantly more effective than placebo and comparable to tricyclic antidepressants for treating depression. More recent meta-analyses confirm these findings. The proposed mechanism is enhancement of monoamine neurotransmitter synthesis (serotonin, dopamine, norepinephrine) through methylation. Importantly, several trials show SAMe augments the effect of antidepressants in people with partial responses — though this must only be done under medical supervision due to drug interaction risks.
- Osteoarthritis: Multiple randomised controlled trials show SAMe reduces joint pain and improves mobility comparably to NSAIDs (ibuprofen, naproxen) with fewer GI side effects. A double-blind trial by Najm et al. (2004) found SAMe equivalent to celecoxib for pain reduction by week 8, with SAMe showing earlier response in functional outcome measures. The proposed mechanism involves SAMe's role in proteoglycan synthesis — the structural components of cartilage.
- Liver health (cholestasis): SAMe is an established medical treatment for intrahepatic cholestasis of pregnancy (ICP) and is used clinically in Europe for liver disease support. It appears to support hepatocyte membrane fluidity and bile flow, and has antioxidant properties in liver tissue. This is one of the most medically validated applications.
- • Fibromyalgia: Some positive studies for pain and mood, but overall evidence is inconsistent
- • ADHD: Preliminary data; insufficient RCT evidence for routine recommendation
- • Alzheimer's / cognitive decline: SAMe levels are lower in Alzheimer's brains, but supplementation trials are limited
SAMe is one of the most chemically unstable supplements on the market. The active form (S,S-SAMe) degrades rapidly when exposed to heat, moisture, and stomach acid. This creates two important purchasing considerations that are specific to this ingredient:
Start low and increase gradually. Begin at 400mg/day for the first week, then increase by 400mg weekly as tolerated. Jumping to a high dose immediately commonly causes nausea and anxiety.
Mood goals: take on an empty stomach. For depression, taking SAMe 30 minutes before meals improves absorption. For joint goals, with or without food is acceptable.
Take B12 and folate alongside SAMe. The methylation cycle that processes SAMe requires both B12 and folate as cofactors. Without adequate levels of these, SAMe metabolism stalls and homocysteine can accumulate. Ensure you're meeting daily requirements for both — ideally check blood levels if supplementing SAMe long-term.
Allow 4–8 weeks. Like antidepressants, SAMe's mood effects often take several weeks to become apparent. Joint benefits may take similar time.
SAMe is pharmacologically active — it is, after all, prescribed as a drug in multiple countries. This means the safety profile requires more attention than a typical supplement.
- Bipolar disorder: SAMe can trigger hypomanic or manic episodes in people with bipolar disorder. This is a well-documented risk and an absolute contraindication. Do not use SAMe if you have a personal or family history of bipolar disorder.
- Taking MAOIs: Combining SAMe with monoamine oxidase inhibitors (a class of antidepressants) risks serotonin syndrome — a potentially life-threatening condition. Never combine these.
- Taking SSRIs or SNRIs without medical supervision: SAMe augments serotonin activity. Combining it with SSRIs or SNRIs may increase serotonin syndrome risk. This combination has been studied in clinical settings under supervision, but should not be done without physician oversight.
- Pregnancy: Insufficient safety data. Not recommended during pregnancy.
- • Nausea and GI discomfort — most common, usually improves after the first week; take with food or reduce dose
- • Anxiety, restlessness, or insomnia — especially at higher doses or when taken late in the day; morning dosing preferred
- • Headache — often transient and resolves with continued use
- • Dry mouth
Note: Given SAMe's pharmacological activity and interaction risks, stacking it with other mood-active supplements (5-HTP, St. John's Wort, tyrosine) without medical guidance is not recommended.
- Hardy ML, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. AHRQ Evidence Report. 2002.
- Najm WI, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms. BMC Musculoskelet Disord. 2004;5:6.
- Papakostas GI, et al. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder. Am J Psychiatry. 2010;167(8):942–948.
Evidence-based supplement recommendations from a former physical store owner. No hype. No BS. Just facts.
Download Free PDF